FY2020 Q1 Financial Results Presentation

from the beginning

FY2020 Q1 Financial Results Presentation

Forward-Looking Statements

Actions Against COVID-19

Update on Actions Against COVID-19

DS-1062 Strategic Collaboration

DS-1062 Strategic Collaboration

FY2020 Q1 Financial Results

Overview of FY2020 Q1 Results

Revenue

Operating Profit

Special Items

Profit Attributable to Owners of the Company

Revenue: Major Business Units (incl. Forex Impact)

Revenue: Major Products in Japan

FY2020 Forecast

FY2020 Consolidated Forecast Update

Business Update

ENHERTU: Performance in US and Japan

R&D Update

3 ADC Update

DS-8201: Clinical Development Plan

DS-8201: Clinical Development Plan

DS-8201: DESTINY-Breast05 Study

DS-8201: DESTINY-Gastric03 Study

DS-8201: Gastric (DESTINY-Gastric01 Study)

DS-8201: NSCLC (DESTINY-Lung01 Study)

DS-8201: CRC (DESTINY-CRC01 Study)

DS-1062: NSCLC (Phase 1 Study)

News flow

News Flow

Appendix

Major R&D Milestones in FY2020

Major R&D Pipeline: 3 ADCs

Major R&D Pipeline: Alpha

Projects for Out-Licensing

Abbreviations

@

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7